(Fighting New Coronary Pneumonia) Hong Kong experts recommend approval of Kexing vaccine for ages ranging from 3 to 17 years old
China News Service, Hong Kong, November 15th. The Hong Kong New Coronary Vaccine Advisory Committee held a meeting on the 15th to approve the continued benefits and risk assessment of the new crown vaccine. It said that after considering the relevant information, it is recommended that the applicable age for the approval of the Kexing vaccine covers 3 to 17 years old. It is also recommended that the SAR government and Fosun Pharma follow up the issue of lowering the age of vaccination and require Fosun Pharma to provide relevant information.
According to reports, at the meeting held on the same day, the advisory expert committee reviewed the relevant information submitted by Kexing regarding Kexing’s application for lowering the vaccination age to 3 years old, including the first and the first published in peer-reviewed medical journals. Phase II clinical research data, real-world safety data collected in Mainland China, preliminary data from Phase III clinical research conducted in South Africa and Chile, and other relevant clinical research data, etc.
Relevant data show that Kexing vaccine has good safety in children of different races from 3 to 17 years old, and compared with adults aged 18 or above, children aged 3 to 17 will produce higher immunogens Sexual response.
After considering the relevant information and measuring the risk of the new crown epidemic to Hong Kong, the advisory expert committee recommended that the scope of application of the Kexing vaccine should be approved to cover children aged 3 to 17.
In addition, regarding the vaccination of Fubital vaccine for children aged 5 to 11, the advisory expert committee has been informed of the relevant clinical data that has been published and the emergency use authorization in overseas areas.
The advisory expert committee recommended that the SAR government and Fosun Pharma follow up the issue of lowering the age of vaccination and request Fosun Pharma to provide relevant information.
A spokesperson for the SAR government said that the SAR government welcomes recommendations from the Advisory Expert Committee on lowering the age of application of Kexing vaccine. After the joint scientific committee reviews, the Secretary for Food and Health of the SAR government will consider the recommendations and make a decision as soon as possible.
The SAR government will also follow up with Fosun Pharma regarding the applicable age of Fubitai vaccine for children aged 5 to 11 years.
The SAR government will continue to ensure that the approved vaccine meets the safety, efficacy and quality requirements, and announce the latest safety and scientific information about the vaccine to the public and relevant stakeholders in a timely manner.
(over)